Hepatocellular carcinoma (hcc) Trials in Beijing, China
Conditions / Hepatocellular carcinoma (hcc) / Beijing, China
Hepatocellular carcinoma (hcc) has been the subject of sustained clinical investigation across multiple research sites.
21 total trials for this combination
Showing top 10 of 21 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07010588 | Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk | NOT_YET_RECRUITING | NA |
| NCT01761266 | A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma | COMPLETED | PHASE3 |
| NCT06712017 | Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China | ENROLLING_BY_INVITATION | — |
| NCT07170345 | Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion | RECRUITING | — |
| NCT03236649 | The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects | TERMINATED | PHASE3 |
| NCT07327034 | ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression | RECRUITING | PHASE2 |
| NCT06487559 | A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) | RECRUITING | PHASE1 |
| NCT07557225 | 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors | NOT_YET_RECRUITING | — |
| NCT03419897 | Study of BGB-A317 in Participants With Previously Treated Unresectable HCC | COMPLETED | PHASE2 |
| NCT03412773 | A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) | COMPLETED | PHASE3 |